<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2803221890
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ARBAVAL PLUS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VALSARTAN,HYDROCHLOROTHIAZIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        320,25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        37.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Arbaval Plus film-coated tablets contain two active substances called valsartan and hydrochlorothiazide.</p><p>Both of these substances help to control high blood pressure (hypertension).</p><p><strong>-Valsartan</strong> belongs to a class of medicines known as &quot;angiotensin II receptor antagonists&quot;, which help to control high blood pressure. Angiotensin II is a substance in the body that causes vessels to tighten, thus causing your blood pressure to Increase.</p><p>Valsartan works by blocking the effect of angiotensin II. As a result, blood vessels relax and blood pressure Is lowered.</p><p>-&nbsp;&nbsp;&nbsp; Hydrochlorothiazide belongs to a group of medicines called thiazide diuretics (also known as &ldquo;water tablets&rdquo;). Hydrochlorothiazide increases urine output, which also lowers blood pressure. Arbaval Plus is used to treat high blood pressure which is not adequately controlled by a single substance alone.</p><p>High blood pressure increases the workload of the heart and arteries. If not treated, it can damage the blood vessels of the brain, heart, and kidneys, and may result in a stroke, heart failure or kidney failure.</p><p>High blood pressure increases the risk of heart attacks. Lowering your blood pressure to normal reduces the risk of developing these disorders.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Arbaval Plus:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic (hypersensitive) to valsartan, hydrochlorothiazide, sulphonamide derivatives (substances chemically related to hydrochlorothiazide) or to any of the</p><p>other ingredients of <strong>Arbaval Plus</strong>.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are more than 3 months pregnant (it is also better to avoid Arbaval Plus in early pregnancy - see pregnancy section).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Arbaval Plus should not be co-administered with aliskiren in patients with diabetes mellitus or renal impairment</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe liver disease, destruction of the small bile ducts within the liver (biliary cirrhosis) leading to the buildup of bile in the liver (cholestasis).</p><p>&bull;&nbsp;&nbsp;&nbsp; If you have severe kidney disease.</p><p>■&nbsp;&nbsp; If you are unable to produce urine (anuria).</p><p>&bull;&nbsp;&nbsp;&nbsp; If you are treated with an artificial kidney.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the level of potassium or sodium in your blood is lower than normal, or if the level of calcium in your blood is higher than normal despite treatment.</p><p>&bull;&nbsp;&nbsp;&nbsp; If you have gout.</p><p>■&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine called aliskiren.</p><p>If any of the above apply to you, do not take this medicine and speak to your doctor. Take special care with Arbaval Plus</p><p>&bull;&nbsp;&nbsp;&nbsp; Dual Blockade of the Renin-Angiotensin-aldosterone System (RAAS):</p><p>Combination of Arbaval Plus with ACE inhibitors, or aliskiren may cause increased risks of hyperkalemia, worsening of kidney function and hypotension. Therefore, this combination should not be used, especially in patients with kidney problems.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking potassium-sparing medicines, potassium supplements, salt substitutes containing potassium or other medicines that increase the amount of potassium in your blood such as heparin. Your doctor may need to check the amount of potassium in your blood regularly.</p><p>&bull;&nbsp;&nbsp;&nbsp; If you have low levels of potassium in your blood.</p><p>&bull;&nbsp;&nbsp;&nbsp; If you have diarrhoea or severe vomiting.</p><p>&bull;&nbsp;&nbsp;&nbsp; If you are taking high doses of water tablets (diuretics).</p><p>&bull;&nbsp;&nbsp;&nbsp; if you have severe heart disease.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are suffering from heart failure or have experienced a heart attack. Follow your doctor&#39;s instruction for the starting dose carefully. Your doctor may also check your kidney function.</p><p>&bull;&nbsp;&nbsp;&nbsp; if you suffer from a narrowing of the kidney artery.</p><p>&bull;&nbsp;&nbsp;&nbsp; if you have recently received a new kidney.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from hyperaldosteronism. This is a disease in which your adrenal glands make too much of the hormone aldosterone. If this applies to you, the use of Arbaval Plus is not recommended.</p><p>&bull;&nbsp;&nbsp;&nbsp; if you have liver or kidney disease.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever experienced swelling of the tongue and face caused by an allergic reaction called angioedema when taking another drug (including ACE inhibitors), tell your doctor. If these symptoms occur when you are taking Arbaval Plus, stop taking Arbaval Plus immediately</p><p>and never take it again. See also section 4, &ldquo;Possible side effects&rdquo;.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have fever, rash and joint pain, which may be signs of systemic lupus erythematosus (SLE, a so-called autoimmune disease).</p><p>&bull;&nbsp;&nbsp;&nbsp; if you have diabetes, gout, high levels of cholesterol or triglycerides in your blood.</p><p>■&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had allergic reactions with the use of other blood pressure-lowering agents of this class (angiotensin II receptor antagonists) or if you have allergy or asthma.</p><p>■&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience a decrease in vision or eye pain. These could be symptoms of an increase of pressure in your eye and can happen within hours to a week of taking Arbaval Plus. This can lead to permanent vision loss, if not treated. If you earlier have had a penicillin or sulphonamide allergy you can be at higher risk of developing this.</p><p>&bull;&nbsp;&nbsp;&nbsp; it may cause increased sensitivity of the skin to sun.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the use of Arbaval Plus in children and adolescents below the age of 18 years is not recommended.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you must tell your doctor if you think you are (or might become) pregnant. Arbaval Plus is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).</p><p>&bull;&nbsp;&nbsp;&nbsp; if you are taking any of the following medicines used to treat high blood pressure:</p><p>-&nbsp;&nbsp;&nbsp; &quot;ACE inhibitors&rdquo; such as enalapril, lisinopril, etc.</p><p>-&nbsp;&nbsp;&nbsp; Aliskiren</p><p><strong>If any of these apply to you, talk to your doctor.</strong></p><p><strong>Taking other medicines</strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p>The effect of the treatment can be Influenced If Arbaval Plus Is taken together with certain other medicines. It may be necessary to change the dose, to take other precautions, or In some cases to stop taking one of the medicines. This especially applies to the following medicines:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dual RAAS Blockade, The combination of Arbaval Plus with Aliskiren, ACEIs or other ARBs is contraindicated in patients with diabetes mellitus or renal impairment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dual blockade (e.g by adding ACE inhibitor to Arbaval Plus) should not be used, especially in patients with Kidney problems.</p><p>-&nbsp;&nbsp;&nbsp; lithium, a medicine used to treat some types of psychiatric diseases.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines or substances that may increase the amount of potassium in your blood. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that may reduce the amount of potassium in your blood, such as diuretics (water tablets), corticosteroids, laxatives, carbenoxolone, amphotericin or penicillin G.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some antibiotics (rifamycin group), a drug used to protect against transplant rejection (ciclosporin) or an antiretroviral drug used to treat HIV/AIDS infection (ritonavir). These drugs may increase the effect of Arbaval Plus.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that may induce torsades de pointes &quot;(irregular heart beat), such as antiarrhythmics (medicines used to treat heart problems) and some arrtipsychotics.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that may reduce the amount of sodium in your blood, such as antidepressants, antipsychotics, anti-epileptics.</p><p>-&nbsp;&nbsp;&nbsp; medicines for the treatment of gout, such as allopurinol, probenecid, sulfinpyrazone.</p><p>-&nbsp;&nbsp;&nbsp; therapeutic vitamin D and calcium supplements.</p><p>-&nbsp;&nbsp;&nbsp; medicines for the treatment of diabetes (oral agents such as metformin or insulins).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines to lower your blood pressure including methyldopa, ACE inhibitors (such as enalapril, lisinopril, etc.) or aliskiren.</p><p>-&nbsp;&nbsp;&nbsp; medicines to increase blood pressure, such as noradrenaline or adrenaline.</p><p>-&nbsp;&nbsp;&nbsp; digoxin or other digitalis glycosides (medicines used to treat heart problems).</p><p>-&nbsp;&nbsp;&nbsp; medicines that may increase blood sugar levels, such as diazoxide or beta blockers.</p><p>-&nbsp;&nbsp;&nbsp; cytotoxic medicines (used to treat cancer), such as methotrexate or cyclophosphamide.</p><p>-pain killers such as non-steroidal anti-inflammatory agents (NSAIDs), including selective cyclooxygenase-2 inhibitors (Cox-2 inhibitors) and acetyl sal icy lie acid &gt;3g.</p><p>-&nbsp;&nbsp;&nbsp; muscle relaxing medicines, such as tubocurarine.</p><p>-anti-cholinergic medicines (medicines used to treat a variety of disorders such as gastrointestinal cramps, urinary bladder spasm, asthma, motion sickness, muscular spasms, Parkinson&#39;s disease and as an aid to anaesthesia).</p><p>-amantadine (medicine used to treat Parkinson&#39;s disease and also used to treat or prevent certain illnesses caused by viruses).</p><p>-&nbsp;&nbsp;&nbsp; cholestyramine and colestipol (medicines used mainly to treat high levels of lipids in the blood).</p><p>-&nbsp;&nbsp;&nbsp; ciclosporin, a medicine used for organ transplant to avoid organ rejection.</p><p>-alcohol, sleeping pills and anaesthetics (medicines with sleeping or palnkllllng effect used for example during surgery).</p><p>-&nbsp;&nbsp;&nbsp; Iodine contrast media (agents used for Imaging examinations).</p><p><strong>Taking Arbaval Plus with food and drink</strong></p><p>You can take Arbaval Plus with or without food.</p><p>Avoid taking alcohol until you have talked to your doctor. Alcohol may make your blood pressure fall more and/or increase the risk of you becoming dizzy or feeling faint.</p><p><strong>Pregnancy and breast-feeding </strong></p><p><strong>Pregnancy:</strong></p><p>You must tell your doctor If you think that you are (or might become) pregnant</p><p>Your doctor will normally advise you to stop taking Arbaval Plus before you become pregnant or as soon as you know you are pregnant, and will advise you to take another medicine instead of Arbaval Plus. Arbaval Plus is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if it is used after the third month of pregnancy.</p><p><strong>Breast-feeding:</strong></p><p><strong>Tell your doctor If you are breast feeding or about to start breast feeding</strong></p><p>Arbaval Plus Is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby Is newborn, or was born prematurely.</p><p>Driving and using machines</p><p>Before you drive a vehicle, use tools or operate machines or cany out other activities that require concentration, make sure you know how Arbaval Plus affects you. Like many other medicines used to treat high blood pressure, Arbaval Plus may occasionally cause dizziness and affect the ability to concentrate.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Arbaval Plus exactly as your doctor has told you. This will help you to get the best results and lower the risk of side effects. You should check with your doctor or pharmacist if you are not sure. People with high blood pressure often do not notice any signs of this problem. Many may feel quite normal. This makes it all the more important for you to keep your appointments with your doctor even if you are feeling well.</p><p>Your doctor will tell you exactly how many tablets of Arbaval Plus to take. Depending on how you respond to the treatment, your doctor may suggest a higher or lower dose.</p><p>&bull; The usual dose of Arbaval Plus is one tablet per day.</p><p>■&nbsp;&nbsp; Do not change the dose or stop taking the tablets without consulting your doctor</p><p>■&nbsp;&nbsp; The medicine should be taken at the same time each day, usually in the morning</p><p>■&nbsp;&nbsp; You can take Arbaval Plus with or without food.</p><p>■&nbsp;&nbsp; Swallow the tablet with a glass of water.</p><p><strong>If you take more Arbaval Plus than you should</strong></p><p>if you experience severe dizziness and/or fainting, lie down and contact your doctor Immediately.</p><p>If you have accidentally taken too many tablets, contact your doctor, pharmacist or hospital.</p><p><strong>If you forget to taka Arbaval Plus</strong></p><p>If you forget to take a dose, take It as soon as you remember. However, If It Is almost time for your next dose, skip the dose you missed.</p><p>Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Arbaval Plus</strong></p><p>Stopping your treatment with Arbaval Plus may cause your high blood pressure to get worse.</p><p>Do not stop taking your medicine unless your doctor tells you to.</p><p><strong>If you have any further questions on the use of this product, ask your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Arbaval Plus can cause side effects, although not everybody gets them. These side effects may occur with certain frequencies, which are defined as follows:</p><p>-&nbsp;&nbsp;&nbsp; very common: affects more than 1 user in 10</p><p>-&nbsp;&nbsp;&nbsp; common: affects 1 to 10 users in 100</p><p>-&nbsp;&nbsp;&nbsp; uncommon: affects 1 to 10 users in 1,000</p><p>-&nbsp;&nbsp;&nbsp; rare: affects 1 to 10 users in 10,000</p><p>-&nbsp;&nbsp;&nbsp; very rare: affects less than 1 user in 10,000</p><p>-&nbsp;&nbsp;&nbsp; not known: frequency cannot be estimated from the available data Some side effects can be serious and need immediate medical attention:</p><p>You should see your doctor immediately if you experience symptoms of angioedema, such as:</p><p>-&nbsp;&nbsp;&nbsp; swollen face, tongue or pharynx</p><p>-&nbsp;&nbsp;&nbsp; difficulty in swallowing</p><p>-&nbsp;&nbsp;&nbsp; hives and difficulties in breathing</p><p>If you get any of these symptoms, stop taking Arbaval Plus and contact your doctor straight away (see also section 2 &ldquo;Take special care with Arbaval Plus&rdquo;).</p><p>Other side effects include:</p><p><strong>Uncommon:</strong></p><p>Cough ,low blood pressure ,light-headedness .dehydration (with symptoms of thirst, dry mouth and tongue, infrequent urination,dark colored urine.dry skinj.muscle pain, tiredness, ting ling or numbness, blurred vision .noises (e.g. hissing, buzzing) in ears</p><p><strong>Very rare:</strong></p><p>Dizziness, diarrhea or joint pain</p><p><strong>Not known:</strong></p><p>-&nbsp;&nbsp;&nbsp; breathing difficulty, severely decreased urine output, low level of sodium in the blood (which can trigger tiredness, confusion, muscle twitching and / or convulsions in severe cases)</p><p>-&nbsp;&nbsp;&nbsp; low level of potassium in the blood (sometimes with muscle weakness, muscle spasms, abnormal heart rhythm)</p><p>-&nbsp;&nbsp;&nbsp; low level of white cells in the blood (with symptoms such as fever, skin infections, sore throat or mouth ulcers due to Infections, weakness)</p><p>-&nbsp;&nbsp;&nbsp; the level of bilirubin increased in blood (which can, in severe cases, trigger yellow skin and eyes)</p><p>-&nbsp;&nbsp;&nbsp; the level of blood urea nitrogen and creatinine increased in blood (which can indicate abnormal kidney function). the level of uric acid in blood increased (which can, in severe cases, trigger gout), syncope (fainting)</p><p>The following side effects have been reported with products containing valsartan or hydrochlorothiazide alone:</p><p>&bull;&nbsp;&nbsp;&nbsp; <strong>Valsartan </strong></p><p><strong>Uncommon:</strong></p><p>spinning sensation, abdominal pain</p><p><strong>Not known:</strong></p><p>-&nbsp;&nbsp;&nbsp; skin rash with or without itching together with some of the following signs or symptoms: fever, joint pain, muscle pain, swollen lymph nodes and/or flu-like symptoms</p><p>-&nbsp;&nbsp;&nbsp; rash, purplished-red spots, fever, itching (symptoms of inflammation of blood vessels)</p><p>-&nbsp;&nbsp;&nbsp; low level of blood platelets (sometimes with unusual bleeding or bruising)</p><p>-&nbsp;&nbsp;&nbsp; high level of potassium in the blood (sometimes with muscle spasms, abnormal heart rhythm)</p><p>-&nbsp;&nbsp;&nbsp; allergic reactions (with symptoms such as rash, itching, hives, difficulty breathing or swallowing, dizziness)</p><p>-&nbsp;&nbsp;&nbsp; swelling mainly of the face and throat: rash; itching</p><p>-&nbsp;&nbsp;&nbsp; elevation of liver function values</p><p>the level of haemoglobin decreased and the percentage of red cells decreased in the blood (which both can, in severe cases, trigger an anaemia).</p><p>-&nbsp;&nbsp;&nbsp; kidney failure</p><p>-&nbsp;&nbsp;&nbsp; low level of sodium in the blood (which can trigger tiredness, confusion, muscle twitching and/or convulsions in severe cases)</p><p>&bull;&nbsp;&nbsp;&nbsp; <strong>Hydrochlorothiazide </strong></p><p><strong>Very common:</strong></p><p>low level of potassium in the blood, increase of lipids in the blood</p><p><strong>Common:</strong></p><p>-&nbsp;&nbsp;&nbsp; low level of sodium in the blood</p><p>-&nbsp;&nbsp;&nbsp; low level of magnesium in the blood</p><p>-&nbsp;&nbsp;&nbsp; high level of uric acid in the blood</p><p>-&nbsp;&nbsp;&nbsp; itchy rash and other types of rash</p><p>-&nbsp;&nbsp;&nbsp; reduced appetite</p><p>-&nbsp;&nbsp;&nbsp; mild nausea and vomiting</p><p>-&nbsp;&nbsp;&nbsp; dizziness, fainting on standing up</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; inability to achieve or maintain erection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; <strong>Rare:</strong></p><p>-&nbsp;&nbsp;&nbsp; swelling and blistering of the skin (due to increased sensitivity to sun)</p><p>-high level of calcium in the blood</p><p>-high level of sugar in the blood</p><p>-&nbsp;&nbsp;&nbsp; sugar in the urine</p><p>-&nbsp;&nbsp;&nbsp; worsening of diabetic metabolic state</p><p>-&nbsp;&nbsp;&nbsp; constipation, diarrhoea, discomfort of the stomach or bowels, liver disorders which can occur together with yellow skin and eyes</p><p>-&nbsp;&nbsp;&nbsp; irregular heart beat</p><p>-&nbsp;&nbsp;&nbsp; headache</p><p>-&nbsp;&nbsp;&nbsp; sleep disturbances</p><p>-&nbsp;&nbsp;&nbsp; sad mood (depression)</p><p>-&nbsp;&nbsp;&nbsp; low level of blood platelets (sometimes with bleeding or bruising underneath the skin)</p><p>-&nbsp;&nbsp;&nbsp; dizziness</p><p>-&nbsp;&nbsp;&nbsp; tingling or numbness</p><p>-&nbsp;&nbsp;&nbsp; vision disorder</p><p><strong>Very rare:</strong></p><p>-&nbsp;&nbsp;&nbsp; inflammation of blood vessels with symptoms such as rash, purplish-red spots, fever (vasculitis) rash, itching, hives, difficulty breathing or swallowing, dizziness (hypersensitivity reactions) severe skin disease that causes rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (toxic epidermal necrolysis)</p><p>-&nbsp;&nbsp;&nbsp; facial rash, joint pain, musde disorder, fever (lupus erythematosus) severe upper stomach pain (pancreatitis)</p><p>difficulty breathing with fever, coughing, wheezing, breathlessness (respiratory distress including pneumonitis and pulmonary oedema) fever, sore throat, more frequent infections (agranulocytosis)</p><p>-&nbsp;&nbsp;&nbsp; pale skin, tiredness, breathlessness, dark urine (haemolytic anaemia)</p><p>-&nbsp;&nbsp;&nbsp; fever, sore throat or mouth ulcers due to infections (leucopenia)</p><p>-&nbsp;&nbsp;&nbsp; confusion, tiredness, muscle twitching and spasm, rapid breathing (hypochloraemic alkalosis)</p><p><strong>Not known:</strong></p><p>-&nbsp;&nbsp;&nbsp; weakness, bruising and frequent infections (aplastic anemia)</p><p>-&nbsp;&nbsp;&nbsp; severely decreased urine output (possible signs of renal disorder or renal failure)</p><p>-&nbsp;&nbsp;&nbsp; decrease in vision or pain in your eyes due to high pressure (possible signs of acute angle-closure glaucoma)</p><p>-&nbsp;&nbsp;&nbsp; rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (possible signs of erythema multiforme)</p><p>-&nbsp;&nbsp;&nbsp; muscle spasm</p><p>-&nbsp;&nbsp;&nbsp; fever (pyrexia)</p><p>-&nbsp;&nbsp;&nbsp; weakness (asthenia)</p><p><strong>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from moisture.</p><p>Do not use Arbaval Plus after the expiry date which is stated on the pack. The expiry date refers to the last day of that month.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>The active ingredients are </strong>Valsartan and Hydrochlorothiazide.</p><p>Arbaval Plus 160/12.5 contains 160mg of Valsartan and 12.5 mg of hydrochlorothiazide. Arbaval Plus 160/25 contain 160mg of Valsartan and 25 mg of hydrochlorothiazide Arbaval Plus 320 /25 mg contain 320 mg of Valsartan and 25 mg of hydrochlorothiazide. <strong>The other Ingredients are:</strong> Silicified Microcrystalline Cellulose crospovidone, Sodium Starch Glycolate, Magnesium stearate, Opdry yellow</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Arbaval Plus 160/12.5 Tables Is Reddish Yellow Oval Shape Film Coated tablet embossed with SJ377 from one side.
Arbaval Plus 160/25 Tablet is Reddish yellow Oval shape Rim Coated tablet embossed with SJ375 from one side.
Arbaval Plus 320/25 Tablet is Reddish yellow Oval shape Film Coated tablet embossed with SJ373 from one side.
All Packs contain 28 film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SAJA Pharmaceuticals</p><p>Saudi Arabian Japanese pharmaceutical company limited Jeddah - Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                July/2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي أربافال بلس على مادتين فعالتين تسميان فالسارتان وهيدروكلوروثيازايد.</p><p dir="RTL">يساعد كل من هاتين المادتين على التحكم في ضغط الدم المرتفع (فرط ضغط الدم)</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينتمي فالسارتان إلى مجموعة من الأدوية تعرف مناهضات مستقبلات أنجيوتنسين-II. أنجيوتنسين-II هي مادة في الجسم تؤدي إلى انقباض الأوعية، مما يسبب ارتفاع ضغط الدم. يعمل فالسارتان عن طريق حصر تأثير أنجيوتنسين-II. نتيجة لذلك، ترتخي الأوعية الدموية، فيقل ضغط الدم لديك.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينتمي هيدروكلوروثيازايد إلى مجموعة من الأدوية تسمى مدرات البول الثيازيدية (تعرف أيضاً باسم &quot;أقراص الماء&quot;). يزيد هيدروكلوروثيازايد إخراج البول، مما يخفض أيضاً ضغط الدم.</p><p dir="RTL">يستخدم أربافال بلس لعلاج ارتفاع ضغط الدم غير المتحكم به بشكل كاف بمادة واحدة فقط.</p><p dir="RTL">يزيد ارتفاع ضغط الدم من عبء عمل القلب والشرايين. إذا لم تتم معالجته، فيمكن أن يتلف الأوعية الدموية بالمخ والقلب والكلى، وقد يؤدي إلى سكتة دماغية أو فشل القلب أو الفشل الكلوي.</p><p dir="RTL">يزيد ارتفاع ضغط الدم من نسبة خطورة الإصابة بنوبات قلبية. يؤدي خفض ضغط الدم إلى الوضع الطبيعي إلى الحد من خطر الإصابة بهذه الاضطرابات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تتناول أربافال بلس في الحالات الأتية:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الحساسية (فرط الحساسية) تجاه فالسارتان أو هيدروكلوروثيازايد<strong> </strong>أو مشتقات السلفوناميد (المواد المرتبطة كيميائياً بالهيدروكلوروثيازايد) أو تجاه أي من المكونات الأخرى لأربافال بلس<strong>.</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت حاملاً لأكثر من 3 أشهر (من الأفضل أيضاً تجنب تناول أربافال بلس في مراحل الحمل المبكرة-انظري قسم &quot;الحمل&quot;).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم استعمال أربافال بلس مع عقار اليسكارين في المرضى الذين يعانون من مرض السكري أو الفشل الكلوي.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض شديد بالكبد، فقد يحدث تدمير للقنوات الصفراوية الصغيرة داخل الكبد (تليف الكبد الصفراوي) مما يؤدي إلى تراكم العصارة الصفراوية في الكبد (ركود صفراوي).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل شديدة في الكلى.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت غير قادر على إخراج البول (انقطاع البول)<strong>.</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعالج بكلية اصطناعية.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان مستوى البوتاسيوم والصوديوم في دمك أقل من الطبيعي، أو إذا كان مستوى الكالسيوم في دمك أكثر من الطبيعي على الرغم من العلاج.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بمرض النقرس.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بمرض السكري أو تعاني من قصور في وظائف الكلى، ويتم علاجك بدواء خافض لضغط الدم يسمى أليسكيرين.</p><p dir="RTL">لا تتناول&nbsp; هذا الدواء وتحدث إلى طبيبك إذا كان أي من الحالات أعلاه تنطبق عليك.</p><p dir="RTL">توخ حذراً خاصاً مع</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نظام حاصرات الرينين أنجيوتنسين ألدوستيرون (RAAS):</p><p dir="RTL">استعمال عقار أربافال بلس مع مثبطات الإنزيم المحول للأنجيوتنسين، أو عقار اليسكارين قد يسبب مخاطر ارتفاع نسبة البوتاسيوم بالدم، وتدهور وظائف الكلى وانخفاض ضغط الدم. ولذلك، يجب ألا تستعمل هذه العقاقير معاً، خصوصاً في المرضى الذين يعانون من مشاكل في الكلى.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية موفرة للبوتاسيوم أو مكملات البوتاسيوم أو بدائل الملح التي تحتوي على البوتاسيوم أو الأدوية الأخرى التي تزيد من كمية البوتاسيوم في دمك مثل الهيبارين. قد يحتاج طبيبك إلى فحص كمية البوتاسيوم في دمك بانتظام.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مستويات منخفضة من البوتاسيوم في دمك.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بالإسهال أو القيء الشديد.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول جرعات مرتفعة من أقراص الماء (مدرات البول).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أمراض شديدة بالقلب.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فشل القلب أو تعرضت لنوبة قلبية. اتبع تعليمات طبيبك الخاصة بجرعة البدء بعناية. قد يفحص طبيبك أيضاً وظائف الكلى لديك.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من تضيق شريان الكلى.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد قمت مؤخراً بزراعة كلية جديدة.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من فرط الألدوستيرونية. يعد هذا مرضاً تقوم فيه الغدة الكظرية بصنع كمية كبيرة جداً من هرمون الألدوستيرون. إذا انطبق عليك هذا، فلا يوصى باستخدام أربافال بلس.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض بالكبد أو بالكلى.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تعرضت من قبل للإصابة بتورم في اللسان والوجه ناجم عن تفاعل حساسية يسمى الوذمة الوعائية عند تناول عقار أخر (بما في ذلك مثبطات إنزيم تحويل الأنجيوتنسين)، فأخبر طبيبك. إذا حدثت هذه الأعراض عند تناولك أربافال بلس، فتوقف عن تناوله على الفور ولا تتناوله مرة أخرى أبداً. انظر أيضاً قسم: 4&quot;الأثار الجانبيو المحتملة&quot;.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حمى وطفح جلدي وألم بالمفاصل، والتي قد تكون علامات على الإصابة بالذئبة الحمامية الجهازية (ما يسمى: مرض مناعي ذاتي).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بمرض السكري أو مرض النقرس، أو ارتفاع مستويات الكوليسترول أو الدهون الثلاثية في دمك.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت من قبل من تفاعلات حساسية مع استخدام أدوية أخرى خافضة لضغط الدم تنتمي لهذه الفئة (مناهضات مستقبلات أنجيوتنسين-II) أو إذا كنت تعاني من حساسية أو ربو.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تعرضا لانخفاض في الرؤية أو ألم بالعين. يمكن أن تكون هذه أعراض لزيادة ضغط العين، وقد تحدث في غضون ساعات إلى اسابيع من تناول أربافال بلس. يمكن أن يؤدي ذلك إلى فقدان دائم بالبصر، إذا لم يتم علاجه. إذا كنت قد عانيت سابقاً من حساسية تجاه البنيسللين أو السلفوناميد فقد تكون معرضاً لنسبة خطورة أكبر للإصابة بذلك.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يؤدي إلى ارتفاع حساسية الجلد تجاه أشعة الشمس.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينصح باستخدام أربافال بلس للأطفال والمراهقين حتى سن 18 عاماً.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عليك اخبار طبيبك إذا كنت تعتقدين أنك (أو قد تصبحين) حاملاً. لا يوصى بتناول أربافال بلس في مراحل الحمل المبكرة، ويجب عدم تناوله إذا تجاوز حملك الشهر الثالث، حيث قد يلحق بطفلك ضرراً خطيراً إذا تم استعماله في هذه المرحلة (انظري قسم &quot;الحمل&quot;)</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أياً من الأدوية التالية المستخدمة في علاج ارتفاع ضغط الدم:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات إنزيم تحويل الأنجيوتنسين : مثل إنالابريل وليزينوبريل...إلخ&quot;.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أليسكيرين</p><p dir="RTL">إذا كان أي من ذلك ينطبق عليك، فيرجى التحدث إلى طبيبك.</p><p dir="RTL">تناول أربافال بلس مع أدوية أخرى</p><p dir="RTL">يرجى إبلاغ الطبيب أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أية أدوية أخرى، بما في ذلك الأدوية التي حصلت عليها دون وصفة طبية.</p><p dir="RTL">يُمكن أن تتأثر فعّالية العلاج إذا تم تناول أربافال بلس بمصاحبة بعض الأدوية الأخرى. قد يكون من الضروري تغيير الجرعة، واتخاذ احتياطات أخرى، أو في بعض الحالات التّوقف عن تناول أحد الأدوية. ينطبق هذا بشكل خاص على الأدوية التالية:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp; حاصرات الرينين أنجيوتنسين الأدوستيرون المزدوج،</p><p dir="RTL">يمنع استخدام أربافال بلس مع اليسكارين أو مثبطات الإنزيم المحول للأنجيوتنسين أو غيرها من موانع مستقلات الأنجيوتنسين في المرضى الذين يعانون من مرض السكري أو الفشل الكلوي.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم استعمال حاصرات رينين أنجيوتنسين المزدوج (مثالًا مع مثبطات الإنزيم المحول للأنجيوتنسين لدواء أربافال بلس)، وخاصة في المرضى الذين يعانون من مشاكل في الكلى.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp; ليثيوم، دواء يُستخدم لعلاج بعض أنواع الأمراض النفسية.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp; الأدوية أو المواد التي قد تُزيد كمية البوتاسيوم في دمك. تشمل هذه الأدوية مكملات البوتاسيوم أو بدائل الملح التي تحتوي على البوتاسيوم أو الأدوية الموفرة للبوتاسيوم والهيبارين.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي قد تُخفض كمية البوتاسيوم في دمك، مثل مدرات البول) أقراص الماء)، الكورتيكوستيرويدات أو الملينات أو كاربينوكسولون أمفوتريسين أو البنيسللين &quot;ج&quot;.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp; بعض المضادات الحيوية ( مجموعة ريفاميسن)، وهو عقار يُستخدم للحماية من رفض الزرع (سيكلوسبورين) أو عقار مضاد للفيروسات القهقرية يُستخدم لعلاج عدوى فيروس نقص المناعة البشري (HIV)/ الإيدز (ريتونافير). قد تُزيد هذه العقاقير من فعّالية أربافال بلس.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي قد تُسبب &quot;التفاف النقاط (إحدى العلامات برسم القلب)&quot; (عدم انتظام ضربات القلب)، مثل: الأدوية المضادة لاضطرابات النظم القلبي (الأدوية التي تُستخدم لعلاج مشاكل القلب) وبعض مضادات الذهان.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي قد تُقلل كمية الصوديوم في دمك، مثل: مضادات&nbsp; الاكتئاب، مضادات الذهان، مضادات الصرع</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp; أدوية علاج النقرس: مثل ألوبيورينول، وبروبانسيد، وسولفينبيرازون.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp; فيتامين &quot;د&quot; العلاجي ومكملات الكالسيوم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp; أدوية علاج مرض السُكري (الأدوية التي يتم تناولها عن طريق الفم مثل: ميتفورمين).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى لخفض ضغط الدم لديك، وتشمل ميثيل دوبا، ومُثبطات إنزيم تحويل الأنجيوتنسين (مثل: إنالابريل، ليزينوبريل ... إلخ) أو أليسكيرين.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp; أدوية لرفع ضغط الدم، مثل: نورادرينالين أو أدرينالين.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp; ديجوكسين أو جليكوزيدات الديجيتاليس (الأدوية التي تُستخدم لعلاج مشاكل القلب).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي قد تزيز من مستويات السكر في الدم، مثل الديازوكسيد أو حاصرات بيتا.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp; الأدوية السامة للخلايا (التي تستخدم لعلاج السرطان)، مثل ميثوتريكسات أو سيكلوفوسفاميد.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp; مسكنات الألم مثل مضادات الالتهاب غير الستيرويدية (NSAIDs)، بما في ذلك مُثبطات الأكسدة الحلقية-2 الانتقائية (مُثبطات &quot;COX-2&quot;) وحمض أسيتيل الساليسيليك&gt;3جرام.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المرخية للعضلات، مثل توبوكورارين.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة للكولين (الأدوية التي تُستخدم لعلاج العديد من الاضطرابات مثل تقلصات المعدة والأمعاء وتقلص المثانة والربو ودوار الحركة وتشنجات العضلات ومرض باركنسون وكعامل مساعد في التخدير).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp; أمانتادين (دواء يُستخدم لعلاج مرض باركنسون ويُستخدم أيضًا لعلاج أو الوقاية من بعض الأمراض الناجمة عن الفيروسات).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp; كولستيرامين وكوليستيبول (أدوية تُستخدم بشكل رئيسي لعلاج ارتفاع مستويات الدهون في الدم).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين، دواء يُستخدم عند زرع الأعضاء لتجنب رفض العضو.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp; الكحول والحبوب المنومة وأدوية التخدير (أدوية لها تأثير مُنوم أو مُسكِن للألم تُستخدم على سبيل المثال أثناء الجراحة).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp; وسائط التباين المحتوية على اليود (عوامل تُستخدم لفحوصات التصوير).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول أربافال بلس مع الطعام</strong></p><p dir="RTL">يمكنك تناول أربافال بلس مع الطعام أو دونه.</p><p dir="RTL">تجنب تناول الكحوليات حتى تتحدث إلى طبيبك. قد تُودي الكحوليات إلى هبوط ضغط الدم لديك بشكل أكبر و/أو ارتفاع نسبة خطورة إصابتك بالدوخة أو الشعور بالإغماء.</p><p dir="RTL">الحمل والرضاعة الطبيعية</p><p dir="RTL"><strong>الحمل</strong>:</p><p dir="RTL">يجب عليك إخبار طبيبك إذا كنت تعتقدين أنك حامل أو قد تصبحين حاملًا.</p><p dir="RTL">سينصحك طبيبك عادة بالتوقف عن تناول أربافال بلس قبل أن تصبحي حاملًا أو بمجرد أن تعلمي بأنك حامل، وسينصحك بتناول دواء آخر بدلًا من أربافال بلس. لا ينصح باستخدام أربافال بلس في وقت مبكر من الحمل، ويجب ألا يتم تناوله إذا تعدى حملك الشهر الثالث، حيث إنه قد يُسبب أضرارًا خطيرة لطفلك إذا تم استخدامه بعد الشهر الثالث من الحمل.</p><p dir="RTL"><strong>الرضاعة الطبيعية:</strong></p><p dir="RTL">أخبري طبيبك إذا كنت ترضعين طفلك طبيعياً، أو على وشك البدء في إرضاعه طبيعياً. لا يوصى باستخدام أربافال بلس من قبل الأمهات اللاتي تمارسن الرضاعة الطبيعية وقد يختار لك طبيبك علاجاً اخر إذا كنت ترغبين في الإرضاع، خاصة إذا كان طفلك حديث الولادة، أو ولد قبل أوانه (خُدج).</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">قبل قيادة المركبة، أو استخدام الأدوات أو تشغيل الآلات أو القيام بالأنشطة التي تتطلب تركيزاً، تأكد من أنك تعرف كيف يؤثر عليك أربافال بلس، مثله مثل الكثير من الأدوية الأخرى التي تستخدم لعلاج ارتفاع ضغط الدم، قد يسبب أربافال بلس أحياناً دوخة ويؤثر على القدرة على التركيز.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول اربافال بلس دائمًا كما أخبرك طبيبك بالضبط سيساعدك هذا في الحصول على أفضل النتائج ويُخفض خطورة الآثار الجانبية. يجب مراجعة الطبيب او الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية التناول.</p><p dir="RTL">الأشخاص المصابون بارتفاع ضغط الدم غالبًا لا يًلاحظون أي علامات على هذه المشكلة. قد يشعر الكثير بأن الأمور طبيعية تمامًا. هذا يجعل الأمر أكثر أهمية بالنسبة لك للحفاظ على مواعيدك مع طبيبك حتى إذا كنت على ما يرام.</p><p dir="RTL">سيخبرك طبيبك بالضبط كم عدد الأقراص التي ستتناوُلها من أربافال بلس. قد يصف طبيبك جرعة أعلى أو أقل وفقًا إلى كيفية استجابتك للعلاج.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الُمعتادة من أربافال بلس هي قرص واحد في اليوم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تغير الجرعة أو تتوقف عن تناول الأقراص دون استشارة طبيبك.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب تناول الدواء في نفس الوقت من كل يوم. عادةً في الصباح.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك تناول أربافال بلس مع الطعام أو بدونه.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع الأقراص كاملة مع كوب من الماء.</p><p dir="RTL">إذا تناولت كمية أكثر مما يجب من أربافال بلس</p><p dir="RTL">إذا تعرضت لدوخة شديدة و/أو إغماء، استلق واتصل بطبيبك على الفور.</p><p dir="RTL">إذا تناولت كمية كبيرة من الأقراص بطريق الخطأ، فاتصل بالطبيب أو الصيدلي، أو المستشفى.</p><p dir="RTL">ماذا تفعل إذا نسيت تناول أربافال بلس؟</p><p dir="RTL">إذا نسيت تناول إحدى الجرعات، فتناولها بمجرد تذكرك لها. أما إذا حان موعد جرعتك التالية، فتجاوز الجرعة التي نسيتها. لاتتناول جرعة مضاعفة لتعويض الجرعة المنساه.</p><p dir="RTL">إذا توقفت عن تناول أربافال بلس</p><p dir="RTL">التوقف عن تُناول أربافال بلس قد يُسبب لك تفاقم ارتفاع ضغط الدم. لا تتوقف عن تناول دوائك ما لم يخبرك الطبيب بذلك.</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية حول استخدام هذا المنتج، فاستشر طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الادوية، قد يُسبب أربافال بلس اثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">قد تحدث هذه الآثار الجانبية بمعدلات تكرار معينة كما يلي:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شائعة جدًا: تُوثر على أكثر من مستخدم واحد بين كل 10 مستخدم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شائعة: تُوثر على مستخدم واحد إلى 10 مستخدمين من كل 100 مستخدم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غير شائعة: تُوثر على مستخدم واحد إلى 10 مستخدمين من كل 1000 مستخدم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نادرة: تُوثر على مستخدم واحد إلى 10 مستخدمين من كل 1000 مستخدم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نادرة جدًا: تُوثر على أقل من مستخدم واحد من كل 1000 مستخدم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غير معروفة: لا يمكن تقدير معدل تكرار من واقع البيانات المتاحة</p><p dir="RTL">بعض الاثار الجانبية قد تكون خطيرة وتحتاج إلى عناية طبية فورية:</p><p dir="RTL">يجب عليك رؤية طبيبك على الفور إذا تعرضت لأعراض الوذمة الوعائية مثل:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بورم الوجه أو اللسان أو البلعوم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة البلع.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شرى (أرتكاريا) وصعوبات في التنفس.</p><p dir="RTL">إذا أُصبت بأي من هذه الأعراض، فتوقف عن تناول أربافال بلس واتصل بطبيبك على الفور (انظر أيضًا قسم 2&quot; توخ حذرا خاصا مع&quot; عقار أربافال بلس).</p><p dir="RTL">آثار جانبية أخرى وتشمل</p><p dir="RTL">غير شائعة:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعورًا بخفة الرأس</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفافًا (مع أعراض وجفاف الفم واللسان وندرة التبول وبول داكن اللون جفاف الجلد).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألمًا في العضلات.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعبًا.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وخزًا أو تنميلاً.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضوضاء (مثل صفير أو طنين) في الأذنين.</p><p dir="RTL">نادرة جدًا:</p><p dir="RTL"><strong>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>دوخة<strong>.</strong></p><p dir="RTL"><strong>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إسهال.</p><p dir="RTL"><strong>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>آلام المفاصل.</p><p dir="RTL">غير معروفة:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات في التنفس.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض إخراج البول بشكل شديد.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الصوديوم في الدم (مما يُودي إلى تعب، ارتباك، انتفاض عضلي و/أو تشنجات في الحالات الشديدة).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى البوتاسيوم في الدم (أحيانُا مع ضعف العضلات وتقلصات العضلات ونظم قلبي غير طبيعي).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الخلايا البيضاء في الدم (مع أعراض مثل الحُمى وعدوى الجلد أو التهاب الحلق أو تقرحات الفم بسبب العدوى والضعف).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى البيليروبين في الدم (والذي يُمكن، في الحالات الشديدة، أن يؤدي إلى اصفرار الجلد والعينين).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى النيتروجين ويوريا الدم والكرياتينين في الدم (الذي يُمكن أن يُشير إلى اضطراب وظائف الكلى).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى حمض اليوريك في الدم (الذ يمكن أن يؤدي إلى الإصابة بمرض النقرس في الحالات الشديدة).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغشيان (الإغماء).</p><p dir="RTL">تم الإبلاغ عن الآثار الجانبية التالية مع استخدام المنتجات التي تحتوي على فالسارتان أو هيدروكلوروثيازايد كل على حدة:</p><p dir="RTL"><strong>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>فالسارتان.</p><p dir="RTL">غير شائعة:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالدوران.</p><p dir="RTL"><strong>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ألم البطن.</p><p dir="RTL">غير معروفة:</p><p dir="RTL"><strong>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>طفح جلدي مع أو بدون حكة مصحوب ببعض العلامات أو الأعراض التالية: حُمى، آلام بالعضلات، تورم الغدد الليمفاوية و/أو أعراض شبيهة بأعراض الأنفلونزا.</p><p dir="RTL"><strong>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>طفح جلدي<strong>، </strong>بقع حمراء تميل إلى القرمزي، حُمى، حكة (أعراض التهاب الأوعية الدموية).</p><p dir="RTL"><strong>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>انخفاض مستوى<strong> </strong>الصفائح الدموية (أحيانًا مع نزيف غير مُعتاد أو كدمات).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى البوتاسيوم في الدم (أحيانُا مع ضعف العضلات وتقلصات العضلات ونظم قلبي غير طبيعي).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية _مع أعراض مثل الطفح جلدي، حكة، شرى (أرتكاريا)، صعوبة في التنفس أو البلع، دوخة).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم بشكل رئيسي في الوجه والحلق، طفح جلدي، حكة.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع قيم وظائف الكلى.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الهيموجلوبين كما انخفضت النسبة المئوية للكريات الحمراء في الدم (حيث قد يؤدي كل منهما في الحالات الشديدة إلى فقر الدم).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفشل الكلوي.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الصوديوم في الدم (مما يُودي إلى تعب، ارتباك، انتفاض عضلي و/أو تشنجات في الحالات الشديدة).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هيدروكلوروثيازايد</p><p dir="RTL"><strong>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>شائعة جدًا:</p><p dir="RTL"><strong>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>انخفاض مستوى البوتاسيوم في الدم<strong>.</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع نسبة الدهون في الدم.</p><p dir="RTL">شائعة:</p><p dir="RTL"><strong>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>انخفاض مستوى الصوديوم في الدم<strong>.</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى<strong> </strong>الماغنسيوم في الدم.</p><p dir="RTL"><strong>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ارتفاع مستوى حمض اليوريك في الدم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي مصحوب بحكة وأنواع أخرى من الطفح الجلدي.</p><p dir="RTL"><strong>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>انخفاض الشهية.</p><p dir="RTL"><strong>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>غثيان وقيء خفيف.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة، إغماء عند الوقوف.</p><p dir="RTL"><strong>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>عدم القدرة على بلوغ الانتصاب أو المحافظة عليه.</p><p dir="RTL">نادرة:</p><p dir="RTL"><strong>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تورم وتقرحات الجلد (بسبب زيادة الحساسية تجاه أشعة الشمس)</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى الكالسيوم في الدم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى السكر في الدم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود سكر بالبول.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاقم الحالة الاستقلابية لمرضى السكر.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك، إسهال، شعور بعدم الراحة في المعدة أو الأمعاء، اضطرابات بالكبد قد يُصاحبها اصفرار الجلد والعينين.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات القلب غير المنتظمة.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات النوم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مزاج حزين (اكتئاب).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الصفائح الدموية (أحيانًا مع نزيف أو كدمات أسفل الجلد).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وخز أو تنميل.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب الرؤية.</p><p dir="RTL">نادرة جدا:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدموية المصحوبة بأعراض مثل: بقع حمراء تميل إلى القرمزي، حُمي (التهاب الأوعية الدموية).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، حكة، شري (ارتكاريا)، صعوبة في التنفس أو البلع، دوخة، (تفاعلات فرط حساسية).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض شديد بالجلد يُسبب طفحاً جلدياً، احمرار الجلد، تقرحات بالشفتين أو العينين أو الفم، تقشر الجلد، حُمي، (انحلال البشرة النخري التسمُمي).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي بالوجه، ألم بالمفاصل، اضطراب بالعضلات، حُمي (الذئبة الحمامية الجهازية).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم شديد بأعلى المعدة (التهاب البنكرياس).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس، مع حمي، سعال، أزيز بالصدر، طيق التنفس، (أزمة تنفسية تشمل الالتهاب الرئوي والوذمة الرئوية).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُمي، التهاب الحلق، عدوي أكثر تكراراً (ندرة خلايا المحببات).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شحوب الجلد، تعب، ضيق التنفس، بول داكن (فقر الدم الانحلالي) ،</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُمي، التهاب الحلق أو قرح بالفم بسبب العدوي (نقص كريات الدم البيضاء).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك، تعبن انتفاض وتقلص عضلي، تنفس سريع (قلوية ناتجة عن نقص كلوريد الدم).</p><p dir="RTL">غير معروفة:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف، كدمات وعدوي متكررة (فقر الدم اللاتنسجي).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض إخراج البول بشكل شديد (عاملات مُحتملة للإصابة باضطراب او فشل الكلي).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في الرؤية أو ألم في عينيك، بسبب ارتفاع ضغط الدم (علامات مُحتملة للإصابة بالزرق ضيق الزاوية الحاد).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، احمرار الجلد، تقرحات بالشفتين أو العينين أو الفم، تقشر الجلد، حمي (علامات مُحتملة للإصابة باحمرار متعددة الأشكال).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلصات عضلية.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمي.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف (وهن).</p><p dir="RTL">إذا أصبح أي من الأثار الجانبية خطيراً، أو إذا لاحظت أية آثار جانبية غير مدرجة في هذه النشرة، فيرجي إبلاغ الطبيب أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ بعيداً عن متناول ورؤية الأطفال.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ في درجة حرارة أقل من ٣٠ درجة مئوية.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بتخزين الدواء في العبوة الأصلية لحمايته من الرطوبة.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم عبوة اربافال بلس التالفة أو منتهيه الصلاحية. يُشير تاريخ انتهاء صلاحية إلى اليوم الأخير من الشهر.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم التخلص من الأدوية عن طريق مياه الصرف او مع المخلفات المنزلية. اسأل الصيدلي الخاص بك عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها.</p><p dir="RTL">&nbsp;ستساعد تلك الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي فالسارتان<strong> </strong>160 ملج، او 320 ملج وهيدروكلوروثيازايد او 12,5 او 25ملج.</p><p dir="RTL">المكونات غير الفعالة: سيليكا غروية لا مائية، كروسبوفيدون،نشا صوديوم، جليكولات،&nbsp; ستيرات الماغنسيوم، اوبادري اصفر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص اربافال بلس 160/12,5 ملج هي اقراص ذات لون أحمر مصفر وبيضاوية الشكل، على احد الجانبين علامة. &quot; &quot;SJ377</p><p dir="RTL">&nbsp;أقراص اربافال بلس&nbsp; 160/25 ملج هي اقراص ذات لون أحمر مصفر وبيضاوية الشكل، على احد الجانبين علامة. &quot; &quot;SJ375 .</p><p dir="RTL">أقراص اربافال بلس&nbsp; 320/25 ملج هي اقراص ذات لون أحمر مصفر وبيضاوية الشكل، على احد الجانبين علامة. &quot; &quot;SJ373 .</p><p dir="RTL">تحتوي جميع العبوات على 28 قرصاً.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مصنع ساجا للصناعات الدوائية</p><p dir="RTL">الشركة العربية السعودية اليابانية للمنتجات الصيدلانية المحدودة</p><p dir="RTL">جدة -المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يوليو/ 2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Arbaval Plus 320 mg/25 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 320 mg of valsartan and 25 mg of hydrochlorothiazide.
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Arbaval Plus 320/25 Tablet is Reddish yellow Oval shape Film Coated tablet embossed with
SJ373 from one side and Plain from the other side
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of essential hypertension in adults.<br />Arbaval Plus fixed-dose combination is indicated in patients whose blood pressure is not<br />adequately controlled on valsartan or hydrochlorothiazide monotherapy.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />The recommended dose of Arbaval Plus 320 mg/25 mg is one film-coated tablet once daily.<br />Dose titration with the individual components is recommended. In each case, up-titration of<br />individual components to the next dose should be followed in order to reduce the risk of<br />hypotension and other adverse events.<br />When clinically appropriate direct change from monotherapy to the fixed combination may be<br />considered in patients whose blood pressure is not adequately controlled on valsartan or<br />hydrochlorothiazide monotherapy, provided the recommended dose titration sequence for the<br />individual components is followed.<br />The clinical response to Arbaval Plus should be evaluated after initiating therapy and if blood<br />pressure remains uncontrolled, the dose may be increased by increasing either one of the<br />components to a maximum dose of Arbaval Plus 320 mg/25 mg.<br />The antihypertensive effect is substantially present within 2 weeks.<br />In most patients, maximal effects are observed within 4 weeks. However, in some patients 4-8<br />weeks treatment may be required. This should be taken into account during dose titration.<br />If no relevant additional effect is seen with Arbaval Plus 320 mg/25 mg after 8 weeks,<br />treatment with an additional or alternative antihypertensive medicinal product should be<br />considered (see section 5.1).<br />Method of administration<br />Arbaval Plus can be taken with or without food and should be administered with water.<br />Special populations<br />Renal impairment<br />No dose adjustment is required for patients with mild to moderate renal impairment<br />(Glomerular Filtration Rate (GFR) &ge; 30 ml/min). Due to the hydrochlorothiazide component,<br />Arbaval Plus is contraindicated in patients with severe renal impairment (GFR &lt; 30 mL/min) and<br />anuria (see sections 4.3, 4.4 and 5.2). Concomitant use of valsartan with aliskiren is<br />contraindicated in patients with renal impairment (GFR &lt; 60 mL/min/1.73 m2) (see section 4.3).<br />Diabetes Mellitus<br />Concomitant use of valsartan with aliskiren is contraindicated in patients with diabetes mellitus<br />(see section 4.3).<br />Hepatic impairment<br />In patients with mild to moderate hepatic impairment without cholestasis the dose of valsartan<br />should not exceed 80 mg (see section 4.4). No adjustment of the hydrochlorothiazide dose is<br />required for patients with mild to moderate hepatic impairment. Due to the valsartan<br />component, Arbaval Plus is contraindicated in patients with severe hepatic impairment or with<br />biliary cirrhosis and cholestasis (see sections 4.3, 4.4 and 5.2).<br />Elderly<br />No dose adjustment is required in elderly patients.<br />Paediatric patients<br />Arbaval Plus is not recommended for use in children below the age of 18 years due to a lack of<br />data on safety and efficacy.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                − Hypersensitivity to valsartan, hydrochlorothiazide, other sulfonamide-derived medicinal
products or to any of the excipients.
− Second and third trimester of pregnancy (section 4.4 and 4.6).
− Arbaval Plus should not be co-administered with aliskiren in patients with diabetes mellitus or
renal impairment− Severe hepatic impairment, biliary cirrhosis and cholestasis.
− Severe renal impairment (creatinine clearance < 30 ml/min), anuria.
− Refractory hypokalaemia, hyponatraemia, hypercalcaemia, and symptomatic hyperuricaemia.
− Concomitant use of angiotensin receptor antagonists (ARBs) - including valsartan- or of
angiotensin-converting enzyme inhibitors (ACEIs) with aliskiren in patients with diabetes
mellitus or renal impairment (GFR < 60 mL/min/1.73 m2) (see sections 4.4 and 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dual Blockade of the Renin-Angiotensin-aldosterone System (RAAS):<br />Combination of Arbaval Plus with ACE inhibitors or aliskiren may cause increased risks of<br />hyperkalemia, worsening of kidney function and hypotension. Therefore, this combination<br />should not be used, especially in patients with kidney problems.<br />Serum electrolyte changes<br />Valsartan<br />Concomitant use with potassium supplements, potassium-sparing diuretics, salt substitutes<br />containing potassium, or other agents that may increase potassium levels (heparin, etc.) is not<br />recommended. Monitoring of potassium should be undertaken as appropriate.<br />Hydrochlorothiazide<br />Hypokalaemia has been reported under treatment with thiazide diuretics, including<br />hydrochlorothiazide. Frequent monitoring of serum potassium is recommended.<br />Treatment with thiazide diuretics, including hydrochlorothiazide, has been associated with<br />hyponatraemia and hypochloraemic alkalosis. Thiazides, including hydrochlorothiazide,<br />increase the urinary excretion of magnesium, which may result in hypomagnesaemia. Calcium<br />excretion is decreased by thiazide diuretics. This may result in hypercalcaemia.<br />As for any patient receiving diuretic therapy, periodic determination of serum electrolytes<br />should be performed at appropriate intervals.<br />Sodium and/or volume-depleted patients<br />Patients receiving thiazide diuretics, including hydrochlorothiazide, should be observed for<br />clinical signs of fluid or electrolyte imbalance.<br />In severely sodium-depleted and/or volume-depleted patients, such as those receiving high<br />doses of diuretics, symptomatic hypotension may occur in rare cases after initiation of therapy<br />with Arbaval Plus. Sodium and/or volume depletion should be corrected before starting<br />treatment with Arbaval Plus.<br />Patients with severe chronic heart failure or other conditions with stimulation of the reninangiotensin-aldosterone-system<br />In patients whose renal function may depend on the activity of the renin-angiotensinaldosterone system (e.g. patients with severe congestive heart failure), treatment with<br />angiotensin converting enzyme inhibitors has been associated with oliguria and/or progressive<br />azotaemia, and in rare cases with acute renal failure and/or death. Evaluation of patients with<br />heart failure or post-myocardial infarction should always include assessment of renal function.<br />The use of Arbaval Plus in patients with severe chronic heart failure has not been established.<br />Hence it cannot be excluded that because of the inhibition of the renin-angiotensin-aldosterone<br />system the application of Arbaval Plus as well may be associated with impairment of the renal<br />function. Arbaval Plus should not be used in these patients.<br />Renal artery stenosis<br />Arbaval Plus should not be used to treat hypertension in patients with unilateral or bilateral<br />renal artery stenosis or stenosis of the artery to a solitary kidney, since blood urea and serum<br />creatinine may increase in such patients.<br />Primary hyperaldosteronism<br />Patients with primary hyperaldosteronism should not be treated with Arbaval Plus as their<br />renin-angiotensin system is not activated.<br />Aortic and mitral valve stenosis, hypertrophic obstructive cardiomyopathy<br />As with all other vasodilators, special caution is indicated in patients suffering from aortic or<br />mitral stenosis, or hypertrophic obstructive cardiomyopathy (HOCM).<br />Renal impairment<br />No dosage adjustment is required for patients with renal impairment with a creatinine<br />clearance &ge;30 ml/min (see section 4.2). Periodic monitoring of serum potassium, creatinine and<br />uric acid levels is recommended when Arbaval Plus is used in patients with renal impairment.<br />The concomitant use of ARBs - including valsartan- or of ACEIs with aliskiren is contraindicated<br />in patients with renal impairment (GFR &lt; 60 mL/min/1.73 m2) (see sections 4.3 and 4.5).<br />Kidney transplantation<br />There is currently no experience on the safe use of Arbaval Plus in patients who have recently<br />undergone kidney transplantation.<br />Hepatic impairment<br />In patients with mild to moderate hepatic impairment without cholestasis, Arbaval Plus should<br />be used with caution (see sections 4.2 and 5.2). Thiazides should be used with caution in<br />patients with impaired hepatic function or progressive liver disease, since minor alterations of<br />fluid and electrolyte balance may precipitate hepatic coma.<br />History of angioedema<br />Angioedema, including swelling of the larynx and glottis, causing airway obstruction and/or<br />swelling of the face, lips, pharynx, and/or tongue has been reported in patients treated with<br />valsartan; some of these patients previously experienced angioedema with other drugs<br />including ACE inhibitors. Arbaval Plus should be immediately discontinued in patients who<br />develop angioedema, and Arbaval Plus should not be re-administered (see section 4.8).<br />Systemic lupus erythematosus<br />Thiazide diuretics, including hydrochlorothiazide, have been reported to exacerbate or activate<br />systemic lupus erythematosus.<br />Other metabolic disturbances<br />Thiazide diuretics, including hydrochlorothiazide, may alter glucose tolerance and raise serum<br />levels of cholesterol, triglycerides and uric acid. In diabetic patients dosage adjustments of<br />insulin or oral hypoglycaemic agents may be required.<br />Thiazides may reduce urinary calcium excretion and cause an intermittent and slight elevation<br />of serum calcium in the absence of known disorders of calcium metabolism. Marked<br />hypercalcaemia may be evidence of underlying hyperparathyroidism. Thiazides should be<br />discontinued before carrying out tests for parathyroid function.<br />Photosensitivity<br />Cases of photosensitivity reactions have been reported with thiazide diuretics (see section 4.8).<br />If photosensitivity reaction occurs during treatment, it is recommended to stop the treatment.<br />If a re-administration of the diuretic is deemed necessary, it is recommended to protect<br />exposed areas to the sun or to artificial UVA.<br />Pregnancy<br />Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless<br />continued AIIRAs therapy is considered essential, patients planning pregnancy should be<br />changed to alternative anti-hypertensive treatments which have an established safety profile<br />for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped<br />immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and<br />4.6).<br />General<br />Caution should be exercised in patients who have shown prior hypersensitivity to other<br />angiotensin II receptor antagonists. Hypersensitivity reactions to hydrochlorothiazide are more<br />likely in patients with allergy and asthma.<br />Acute Angle-Closure Glaucoma<br />Hydrochlorothiazide, a sulfonamide, has been associated with an idiosyncratic reaction<br />resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute<br />onset of decreased visual acuity or ocular pain and typically occur within hours to week of a<br />drug initiation. Untreated acute-angle closure glaucoma can lead to permanent vision loss.<br />The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt<br />medical or surgical treatment may need to be considered if the intraocular pressure remains<br />uncontrolled. Risk factors for developing acute angle closure glaucoma may include a history of<br />sulfonamide or penicillin allergy.<br />Dual Blockade of the Renin-Angiotensin-Aldosterone System (RAAS)<br />Hypotension, syncope, stroke, hyperkalaemia, and changes in renal function (including acute<br />renal failure) have been reported in susceptible individuals, especially if combining medicinal<br />products that affect this system. Dual blockade of the renin-angiotensin-aldosterone system by<br />combining aliskiren with an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin II<br />receptor blocker (ARB) is therefore not recommended.<br />The use of aliskiren in combination with Diovan Comp is contraindicated in patients with<br />diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see section 4.3).<br />Galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorbtion<br />Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or<br />glucose-galactose malabsorbtion should not take this medicine.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interactions related to both valsartan and hydrochlorothiazide<br />Concomitant use not recommended<br />Dual RAAS Blockade:<br />The combination of Cadioval HCT with Aliskiren, ACEIs or other ARBs is contraindicated in<br />patients with diabetes mellitus or renal impairment.<br />Dual blockade (e.g by adding ACE inhibitor to Cadioval HCT ) should not be used, especially in<br />patients with Kidney problems.<br />Lithium<br />Reversible increases in serum lithium concentrations and toxicity have been reported during<br />concomitant administration of lithium with ACE inhibitors, angiotensin II receptor antagonists<br />or thiazides, including hydrochlorothiazide. Since renal clearance of lithium is reduced by<br />thiazides, the risk of lithium toxicity may presumably be increased further with Arbaval Plus. If<br />the combination proves necessary, a careful monitoring of serum lithium levels is<br />recommended.<br />Concomitant use requiring caution<br />Other antihypertensive agents<br />Arbaval Plus may increase the effects of other agents with antihypertensive properties (e.g.<br />guanethidine, methyldopa, vasodilators, ACEI, ARBs, beta blockers, calcium channel blockers<br />and DRIs).<br />Pressor amines (e.g. noradrenaline, adrenaline)<br />Possible decreased response to pressor amines. The clinical significance of this effect is<br />uncertain and not sufficient to preclude their use.<br />Non-steroidal anti-inflammatory medicines (NSAIDs), including selective COX-2 inhibitors,<br />acetylsalicylic acid (&gt;3 g/day), and non-selective NSAIDs<br />NSAIDS can attenuate the antihypertensive effect of both angiotensin II antagonists and<br />hydrochlorothiazide when administered simultaneously. Furthermore, concomitant use of<br />Arbaval Plus and NSAIDs may lead to worsening of renal function and an increase in serum<br />potassium. Therefore, monitoring of renal function at the beginning of the treatment is<br />recommended, as well as adequate hydration of the patient.<br />Interactions related to valsartan<br />Dual blockade of the Renin-Angiotensin-System (RAS) with ARBs, ACEIs, or aliskiren<br />Caution is required while co-administering ARBs, including valsartan, with other agents blocking<br />the RAAS such as ACEIs or aliskiren (see section 4.4).<br />Concomitant use of angiotensin receptor antagonists (ARBs) - including valsartan &ndash; or of<br />angiotensin-converting-enzyme inhibitors (ACEIs) with aliskiren in patients with diabetes<br />mellitus or renal impairment (GFR &lt;60 mL/min/1.73m2) is contraindicated (see section 4.3).<br />Concomitant use not recommended<br />Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and<br />other substances that may increase potassium levels<br />If a medicinal product that affects potassium levels is considered necessary in combination with<br />valsartan, monitoring of potassium plasma levels is advised.<br />Transporters<br />In vitro data indicates that valsartan is a substrate of the hepatic uptake transporter<br />OATP1B1/OATP1B3 and the hepatic efflux transporter MRP2. The clinical relevance of this<br />finding is unknown. Co-administration of inhibitors of the uptake transporter (eg. rifampin,<br />ciclosporin) or efflux transporter (eg. ritonavir) may increase the systemic exposure to<br />valsartan. Exercise appropriate care when initiating or ending concomitant treatment with such<br />drugs.<br />No interaction<br />In drug interaction studies with valsartan, no interactions of clinical significance have been<br />found with valsartan or any of the following substances: cimetidine, warfarin, furosemide,<br />digoxin, atenolol, indomethacin, hydrochlorothiazide, amlodipine, glibenclamide. Digoxin and<br />indomethacin could interact with the hydrochlorothiazide component of Arbaval Plus (see<br />interactions related to hydrochlorothiazide).<br />Interactions related to hydrochlorothiazide<br />Concomitant use requiring caution<br />Medicinal products affecting serum potassium level<br />The hypokalaemic effect of hydrochlorothiazide may be increased by concomitant<br />administration of kaliuretic diuretics, corticosteroids, laxatives, ACTH, amphotericin,<br />carbenoxolone, penicillin G, salicylic acid and derivatives.<br />If these medicinal products are to be prescribed with the hydrochlorothiazide-valsartan<br />combination, monitoring of potassium plasma levels is advised (see section 4.4).<br />Medicinal products that could induce torsades de pointes<br />Due to the risk of hypokalaemia, hydrochlorothiazide should be administered with caution<br />when associated with medicinal products that could induce torsades de pointes, in particular<br />Class Ia and Class III antiarrhythmics and some antipsychotics, the following drugs could induce<br />torsades de points: bepridil, cisapride, diphemanil, erythromycin i.v., halofantrin, ketanserin,<br />mizolastin, pentamidine, sparfloxacine, terfenadine, vincamine i.v.<br />Medicinal products affecting serum sodium level<br />The hyponatraemic effect of diuretics may be intensified by concomitant administration of<br />drugs such as antidepressants, antipsychotics, antiepileptics, etc. Caution is advised in longterm administration of these drugs.<br />Digitalis glycosides<br />Thiazide-induced hypokalaemia or hypomagnesaemia may occur as undesirable effects<br />favouring the onset of digitalis-induced cardiac arrhythmias (see section 4.4).<br />Calcium salts and vitamin D<br />Administration of thiazide diuretics, including hydrochlorothiazide, with vitamin D or with<br />calcium salts may potentiate the rise in serum calcium. Concomitant use of thiazide type<br />diuretics with calcium salts may cause hypercalcaemia in patients pre-disposed for<br />hypercalcaemia (e.g. hyperparathyroidism, malignancy or vitamin-D-mediated conditions) by<br />increasing tubular calcium reabsorption.<br />Antidiabetic agents (oral agents and insulin)<br />Thiazides may alter glucose tolerance. Dose adjustment of the antidiabetic medicinal product<br />may be necessary.<br />Metformin should be used with caution because of the risk of lactic acidosis induced by possible<br />functional renal failure linked to hydrochlorothiazide.<br />Beta blockers and diazoxide<br />Concomitant use of thiazide diuretics, including hydrochlorothiazide, with beta blockers may<br />increase the risk of hyperglycaemia. Thiazide diuretics, including hydrochlorothiazide, may<br />enhance the hyperglycaemic effect of diazoxide.<br />Medicinal products used in the treatment of gout (probenecid, sulfinpyrazone and allopurinol)<br />Dose adjustment of uricosuric medications may be necessary as hydrochlorothiazide may raise<br />the level of serum uric acid. Increase of dosage of probenecid or sulfinpyrazone may be<br />necessary. Co-administration of thiazide diuretics, including hydrochlorothiazide, may increase<br />the incidence of hypersensitivity reactions to allopurinol.<br />Anticholinergic agents and other medicinal products affecting gastric motility<br />The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents (e.g.<br />atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach<br />emptying rate. Conversely, it is anticipated that prokinetic drugs such as cisapride may decrease<br />the bioavailability of thiazide-type diuretics.<br />Amantadine<br />Thiazides, including hydrochlorothiazide, may increase the risk of adverse effects caused by<br />amantadine.<br />Ion exchange resins<br />Absorption of thiazide diuretics, including hydrochlorothiazide, is decreased by cholestyramine<br />or colestipol. This could result in sub-therapeutic effects of thiazide diuretics. However,<br />staggering the dosage of hydrochlorothiazide and resin such that hydrochlorothiazide is<br />administered at least 4 h before or 4-6 h after the administration of resins would potentially<br />minimise the interaction.<br />Cytotoxic agents<br />Thiazides, including hydrochlorothiazide, may reduce renal excretion of cytotoxic agents (e.g.<br />cyclophosamide, methotrexate) and potentiate their myelosuppressive effects.<br />Non-depolarising skeletal muscle relaxants (e.g. tubocurarine)<br />Thiazides, including hydrochlorothiazide, potentiate the action of skeletal muscle relaxants such<br />as curare derivatives.<br />Ciclosporin<br />Concomitant treatment with ciclosporin may increase the risk of hyperuricaemia and gout-type<br />complications.<br />Alcohol, barbiturates or narcotics<br />Concomitant administration of thiazide diuretics with substances that also have a blood<br />pressure lowering effect (e.g. by reducing sympathetic central nervous system activity or direct<br />vasodilatation activity) may potentiate orthostatic hypotension.<br />Methyldopa<br />There have been isolated reports of haemolytic anaemia in patients receiving concomitant<br />treatment with methyldopa and hydrochlorothiazide.<br />Iodine contrast media<br />In case of diuretic-induced dehydration, there is an increased risk of acute renal failure,<br />especially with high doses of the iodine product. Patients should be rehydrated before the<br />administration.<br />Carbamazepine<br />Patients receiving hydrochlorothiazide concomitantly with Carbamazepine may develop<br />hyponatremia. Such patients should therefore be advised about the possibility of<br />hyponatraemic reactions, and should be monitored accordingly.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy category (D)<br />Pregnancy<br />Valsartan<br />The use of Angiotensin II Receptor Antagonists (AIIRAs) is not recommended during first<br />trimester of pregnancy (see section 4.4).The use of AIIRAs is contra-indicated during the<br />second and third trimester of pregnancy (see sections 4.3 and 4.4).<br />Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE<br />inhibitors during the first trimester of pregnancy has not been conclusive; however a small<br />increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the<br />risk with Angiotensin II Receptor Inhibitors (AIIRAs), similar risks may exist for this class of<br />drugs. Unless continued AIIRAs therapy is considered essential, patients planning pregnancy<br />should be changed to alternative anti-hypertensive treatments which have an established<br />safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should<br />be stopped immediately and, if appropriate, alternative therapy should be started.<br />AIIRAs therapy exposure during the second and third trimesters is known to induce human<br />fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and<br />neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see also section 5.3).<br />Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound<br />check of renal function and skull is recommended.<br />Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see also<br />section 4.3 and 4.4).<br />Hydrochlorothiazide<br />There is limited experience with hydrochlorothiazide during pregnancy, especially during the<br />first trimester. Animal studies are insufficient. Hydrochlorothiazide crosses the placenta. Based<br />on the pharmacological mechanism of action of hydrochlorothiazide its use during the second<br />and third trimester may compromise foeto-placental perfusion and may cause foetal and<br />neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia.<br />Lactation<br />No information is available regarding the use of valsartan during breastfeeding.<br />Hydrochlorothiazide is excreted in human milk. Therefore the use of Arbaval Plus during breast<br />feeding is not recommended. Alternative treatments with better established safety profiles<br />during breast-feeding are preferable, especially while nursing a newborn or preterm infant.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effect of Arbaval Plus on the ability to drive and use machines have been<br />performed. When driving vehicles or operating machines it should be taken into account that<br />occasionally dizziness or weariness may occur.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>a. Summary of the safety profile:<br />Adverse reactions reported in clinical trials and laboratory findings occurring more frequently<br />with valsartan plus hydrochlorothiazide versus placebo and individual postmarketing reports<br />are presented below according to system organ class. Adverse reactions known to occur with<br />each component given individually but which have not been seen in clinical trials may occur<br />during treatment with valsartan/hydrochlorothiazide.<br />b. Tabulated list of Adverse reaction:<br />Adverse reactions previously reported with one of the individual components may be potential<br />undesirable effects with Arbaval Plus as well, even if not observed in clinical trials or during<br />postmarketing period.<br />Adverse drug reactions are ranked by frequency, the most frequent first, using the following<br />convention: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt;<br />1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000), not known (cannot be estimated<br />from the available data). Within each frequency grouping, adverse reactions are ranked in order<br />of decreasing seriousness.<br /><img src="data:image/png;base64,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" alt="" width="526" height="625" vspace="0" hspace="0" border="0" style="width:526px;height:625px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><img src="data:image/png;base64,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" alt="" width="524" height="657" vspace="0" hspace="0" border="0" style="width:524px;height:657px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><img src="data:image/png;base64,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" alt="" width="536" height="211" vspace="0" hspace="0" border="0" style="width:536px;height:211px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>c. Paediatric population<br />Arbaval Plus is not recommended for use in children below the age of 18 years due to a lack<br />of data on safety and efficacy.<br />d. Other special population:<br />Renal impairment<br />No dose adjustment is required for patients with mild to moderate renal impairment<br />(Glomerular Filtration Rate (GFR) &ge; 30 ml/min). Due to the hydrochlorothiazide component,<br />Arbaval Plus is contraindicated in patients with severe renal impairment (GFR &lt; 30 mL/min) and<br />anuria (see sections 4.3, 4.4 and 5.2). Concomitant use of valsartan with aliskiren is<br />contraindicated in patients with renal impairment (GFR &lt; 60 mL/min/1.73 m2) (see section 4.3).<br />Diabetes Mellitus<br />Concomitant use of valsartan with aliskiren is contraindicated in patients with diabetes mellitus<br />(see section 4.3).<br />Hepatic impairment<br />In patients with mild to moderate hepatic impairment without cholestasis the dose of valsartan<br />should not exceed 80 mg (see section 4.4). No adjustment of the hydrochlorothiazide dose is<br />required for patients with mild to moderate hepatic impairment. Due to the valsartan<br />component, Arbaval Plus is contraindicated in patients with severe hepatic impairment or with<br />biliary cirrhosis and cholestasis (see sections 4.3, 4.4 and 5.2).<br />Elderly<br />No dose adjustment is required in elderly patients.<br />Kidney transplantation<br />There is currently no experience on the safe use of Arbaval Plus in patients who have recently<br />undergone kidney transplantation.<br />History of angioedema<br />Angioedema, including swelling of the larynx and glottis, causing airway obstruction and/or<br />swelling of the face, lips, pharynx, and/or tongue has been reported in patients treated with<br />valsartan; some of these patients previously experienced angioedema with other drugs<br />including ACE inhibitors. Arbaval Plus should be immediately discontinued in patients who<br />develop angioedema, and Arbaval Plus should not be re-administered (see section 4.8).<br />Systemic lupus erythematosus<br />Thiazide diuretics, including hydrochlorothiazide, have been reported to exacerbate or activate<br />systemic lupus erythematosus.<br />Other metabolic disturbances<br />Thiazide diuretics, including hydrochlorothiazide, may alter glucose tolerance and raise serum<br />levels of cholesterol, triglycerides and uric acid. In diabetic patients dosage adjustments of<br />insulin or oral hypoglycaemic agents may be required.<br />Thiazides may reduce urinary calcium excretion and cause an intermittent and slight elevation<br />of serum calcium in the absence of known disorders of calcium metabolism. Marked<br />hypercalcaemia may be evidence of underlying hyperparathyroidism. Thiazides should be<br />discontinued before carrying out tests for parathyroid function.<br />Photosensitivity<br />Cases of photosensitivity reactions have been reported with thiazide diuretics (see section 4.8).<br />If photosensitivity reaction occurs during treatment, it is recommended to stop the treatment.<br />If a re-administration of the diuretic is deemed necessary, it is recommended to protect<br />exposed areas to the sun or to artificial UVA.<br />Pregnancy<br />Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless<br />continued AIIRAs therapy is considered essential, patients planning pregnancy should be<br />changed to alternative anti-hypertensive treatments which have an established safety profile<br />for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped<br />immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and<br />4.6).<br />General<br />Caution should be exercised in patients who have shown prior hypersensitivity to other<br />angiotensin II receptor antagonists. Hypersensitivity reactions to hydrochlorothiazide are more<br />likely in patients with allergy and asthma.<br />Acute Angle-Closure Glaucoma<br />Hydrochlorothiazide, a sulfonamide, has been associated with an idiosyncratic reaction<br />resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute<br />onset of decreased visual acuity or ocular pain and typically occur within hours to week of a<br />drug initiation. Untreated acute-angle closure glaucoma can lead to permanent vision loss.<br />The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt<br />medical or surgical treatment may need to be considered if the intraocular pressure remains<br />uncontrolled. Risk factors for developing acute angle closure glaucoma may include a history of<br />sulfonamide or penicillin allergy.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms<br />Overdose with valsartan may result in marked hypotension, which could lead to depressed level<br />of consciousness, circulatory collapse and/or shock. In addition, the following signs and<br />symptoms may occur due to an overdose of the hydrochlorothiazide component: nausea,<br />somnolence, hypovolaemia, and electrolyte disturbances associated with cardiac arrhythmias<br />and muscle spasms.<br />Treatment<br />The therapeutic measures depend on the time of ingestion and the type and severity of the<br />symptoms, stabilisation of the circulatory condition being of prime importance.<br />If hypotension occurs, the patient should be placed in the supine position and salt and volume<br />supplementation should be given rapidly.<br />Valsartan cannot be eliminated by means of haemodialysis because of its strong plasma binding<br />behaviour whereas clearance of hydrochlorothiazide will be achieved by dialysis.<br />&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin II antagonists and diuretics, valsartan and diuretics;<br />ATC code: C09D A03.<br />Valsartan/hydrochlorothiazide<br />In a double-blind, randomised, active-controlled trial in patients not adequately controlled on<br />valsartan 320 mg, significantly greater mean systolic/diastolic BP reductions were observed<br />with both the combination of valsartan/hydrochlorothiazide 320/25 mg (15.4/10.4 mmHg) and<br />valsartan/hydrochlorothiazide 320/12.5 mg (13.6/9.7 mmHg) compared to valsartan 320 mg<br />(6.1/5.8 mmHg).<br />The difference in systolic BP reduction between the 320/25 mg and 320/12.5 mg doses also<br />reached statistical significance. In addition, a significantly greater percentage of patients<br />responded (diastolic BP &lt;90 mmHg or reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide<br />320/25 mg (75%) and 320/12.5 mg (69%) compared to valsartan 320 mg (53%).<br />In a double-blind, randomised, placebo-controlled, factorial design trial comparing various dose<br />combinations of valsartan/hydrochlorothiazide to their respective components, significantly<br />greater mean systolic/diastolic BP reductions were observed with the combination of<br />valsartan/hydrochlorothiazide 320/12.5 mg (21.7/15.0 mmHg) and 320/25 mg (24.7/16.6<br />mmHg) compared to placebo (7.0/5.9 mmHg) and the respective monotherapies, i.e.<br />hydrochlorothiazide 12.5 mg (11.1/9.0 mmHg), hydrochlorothiazide 25 mg (14.5/10.8 mmHg)<br />and valsartan 320 mg (13.7/11.3 mmHg). In addition, a significantly greater percentage of<br />patients responded (diastolic BP &lt;90 mmHg or reduction &ge;10 mmHg) with<br />valsartan/hydrochlorothiazide 320/25 mg (85%) and 320/12.5 mg (83%) compared to placebo<br />(45%) and the respective monotherapies, i.e. hydrochlorothiazide 12.5 mg (60%),<br />hydrochlorothiazide 25 mg (66%), and valsartan 320 mg (69%).<br />Dose-dependent decreases in serum potassium occurred in controlled clinical studies with<br />valsartan + hydrochlorothiazide. Reduction in serum potassium occurred more frequently in<br />patients given 25 mg hydrochlorothiazide than in those given 12.5 mg hydrochlorothiazide. In<br />controlled clinical trials with valsartan/hydrochlorothiazide the potassium lowering effect of<br />hydrochlorothiazide was attenuated by the potassium-sparing effect of valsartan.<br />Beneficial effects of valsartan in combination with hydrochlorothiazide on cardiovascular<br />mortality and morbidity are currently unknown.<br />Epidemiological studies have shown that long-term treatment with hydrochlorothiazide<br />reduces the risk of cardiovascular mortality and morbidity.<br />Valsartan<br />Valsartan is an orally active and specific angiotensin II (Ang II) receptor antagonist. It acts<br />selectively on the AT1 receptor subtype, which is responsible for the known actions of<br />angiotensin II. The increased plasma levels of Ang II following AT1 receptor blockade with<br />valsartan may stimulate the unblocked AT2 receptor, which appears to counterbalance the<br />effect of the AT1 receptor. Valsartan does not exhibit any partial agonist activity at the AT1<br />receptor and has much (about 20,000-fold) greater affinity for the AT1 receptor than for the<br />AT2 receptor. Valsartan is not known to bind to or block other hormone receptors or ion<br />channels known to be important in cardiovascular regulation.<br />Valsartan does not inhibit ACE, also known as kininase II, which converts Ang I to Ang II and<br />degrades bradykinin. Since there is no effect on ACE and no potentiation of bradykinin or<br />substance P, angiotensin II antagonists are unlikely to be associated with coughing. In clinical<br />trials where valsartan was compared with an ACE inhibitor, the incidence of dry cough was<br />significantly (P &lt;0.05) lower in patients treated with valsartan than in those treated with an ACE<br />inhibitor (2.6% versus 7.9% respectively). In a clinical trial of patients with a history of dry cough<br />during ACE inhibitor therapy, 19.5% of trial subjects receiving valsartan and 19.0% of those<br />receiving a thiazide diuretic experienced cough compared to 68.5% of those treated with an<br />ACE inhibitor (P &lt;0.05).<br />Administration of valsartan to patients with hypertension results in reduction of blood pressure<br />without affecting pulse rate. In most patients, after administration of a single oral dose, onset<br />of antihypertensive activity occurs within 2 hours, and the peak reduction of blood pressure is<br />achieved within 4&ndash;6 hours. The antihypertensive effect persists over 24 hours after dosing.<br />During repeated dosing, the maximum reduction in blood pressure with any dose is generally<br />attained within 2&ndash;4 weeks and is sustained during long-term therapy. Combined with<br />hydrochlorothiazide, a significant additional reduction in blood pressure is achieved.<br />Abrupt withdrawal of valsartan has not been associated with rebound hypertension or other<br />adverse clinical events.<br />In hypertensive patients with type 2 diabetes and microalbuminuria, valsartan has been shown<br />to reduce the urinary excretion of albumin. The MARVAL (Micro Albuminuria Reduction with<br />Valsartan) study assessed the reduction in urinary albumin excretion (UAE) with valsartan (80-<br />160 mg/od) versus amlodipine (5-10 mg/od), in 332 type 2 diabetic patients (mean age: 58<br />years; 265 men) with microalbuminuria (valsartan: 58 &micro;g/min; amlodipine: 55.4 &micro;g/min),<br />normal or high blood pressure and with preserved renal function (blood creatinine &lt;120<br />&micro;mol/l). At 24 weeks, UAE was reduced (p &lt;0.001) by 42% (&ndash;24.2 &micro;g/min; 95% CI: &ndash;40.4 to &ndash;<br />19.1) with valsartan and approximately 3% (&ndash;1.7 &micro;g/min; 95% CI: &ndash;5.6 to 14.9) with amlodipine<br />despite similar rates of blood pressure reduction in both groups. The Diovan Reduction of<br />Proteinuria (DROP) study further examined the efficacy of valsartan in reducing UAE in 391<br />hypertensive patients (BP=150/88 mmHg) with type 2 diabetes, albuminuria (mean=102<br />&micro;g/min; 20-700 &micro;g/min) and preserved renal function (mean serum creatinine = 80 &micro;mol/l).<br />Patients were randomised to one of 3 doses of valsartan (160, 320 and 640 mg/od) and treated<br />for 30 weeks. The purpose of the study was to determine the optimal dose of valsartan for<br />reducing UAE in hypertensive patients with type 2 diabetes. At 30 weeks, the percentage<br />change in UAE was significantly reduced by 36% from baseline with valsartan 160 mg (95%CI:<br />22 to 47%), and by 44% with valsartan 320 mg (95%CI: 31 to 54%). It was concluded that 160-<br />320 mg of valsartan produced clinically relevant reductions in UAE in hypertensive patients with<br />type 2 diabetes.<br />Hydrochlorothiazide<br />The site of action of thiazide diuretics is primarily in the renal distal convoluted tubule. It has<br />been shown that there is a high-affinity receptor in the renal cortex as the primary binding site<br />for the thiazide diuretic action and inhibition of NaCl transport in the distal convoluted tubule.<br />The mode of action of thiazides is through inhibition of the Na+Cl- symporter perhaps by<br />competing for the Cl- site, thereby affecting electrolyte reabsorption mechanisms:directly<br />increasing sodium and chloride excretion to an approximately equal extent, and indirectly by<br />this diuretic action reducing plasma volume, with consequent increases in plasma renin activity,<br />aldosterone secretion and urinary potassium loss, and a decrease in serum potassium. The<br />renin-aldosterone link is mediated by angiotensin II, so with co-administration of valsartan the<br />reduction in serum potassium is less pronounced as observed under monotherapy with<br />hydrochlorothiazide.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Valsartan/hydrochlorothiazide<br />The systemic availability of hydrochlorothiazide is reduced by about 30% when co-administered<br />with valsartan. The kinetics of valsartan are not markedly affected by the co-administration of<br />hydrochlorothiazide. This observed interaction has no impact on the combined use of valsartan<br />and hydrochlorothiazide, since controlled clinical trials have shown a clear anti-hypertensive<br />effect, greater than that obtained with either active substance given alone, or placebo.<br />Valsartan<br />Absorption<br />Following oral administration of valsartan alone, peak plasma concentrations of valsartan are<br />reached in 2&ndash;4 hours. Mean absolute bioavailability is 23%. Food decreases exposure (as<br />measured by AUC) to valsartan by about 40% and peak plasma concentration (Cmax) by about<br />50%, although from about 8 h post dosing plasma valsartan concentrations are similar for the<br />fed and fasted groups. This reduction in AUC is not, however, accompanied by a clinically<br />significant reduction in the therapeutic effect, and valsartan can therefore be given either with<br />or without food.<br />Distribution<br />The steady-state volume of distribution of valsartan after intravenous administration is about<br />17 litres, indicating that valsartan does not distribute into tissues extensively. Valsartan is highly<br />bound to serum proteins (94&ndash;97%), mainly serum albumin.<br />Biotransformation<br />Valsartan is not biotransformed to a high extent as only about 20% of dose is recovered as<br />metabolites. A hydroxy metabolite has been identified in plasma at low concentrations (less<br />than 10% of the valsartan AUC). This metabolite is pharmacologically inactive.<br />Elimination<br />Valsartan shows multiexponential decay kinetics (t&frac12;&alpha; &lt;1 h and t&frac12;&szlig; about 9 h). Valsartan is<br />primarily eliminated in faeces (about 83% of dose) and urine (about 13% of dose), mainly as<br />unchanged drug. Following intravenous administration, plasma clearance of valsartan is about 2<br />l/h and its renal clearance is 0.62 l/h (about 30% of total clearance). The half-life of valsartan is<br />6 hours.<br />Hydrochlorothiazide<br />Absorption<br />The absorption of hydrochlorothiazide, after an oral dose, is rapid (tmax about 2 h). The increase<br />in mean AUC is linear and dose proportional in the therapeutic range.<br />The effect of food on hydrochlorothiazide absorption, if any, has little clinical significance.<br />Absolute bioavailability of hydrochlorothiazide is 70% after oral administration.<br />Distribution<br />The apparent volume of distribution is 4&ndash;8 l/kg.<br />Circulating hydrochlorothiazide is bound to serum proteins (40&ndash;70%), mainly serum albumin.<br />Hydrochlorothiazide also accumulates in erythrocytes at approximately 3 times the level in<br />plasma.<br />Elimination<br />Hydrochlorotiazide is eliminated predominantly as unchanged drug. Hydrochlorothiazide is<br />eliminated from plasma with a half-life averaging 6 to 15 hours in the terminal elimination<br />phase. There is no change in the kinetics of hydrochlorothiazide on repeated dosing, and<br />accumulation is minimal when dosed once daily. There is more than 95% of the absorbed dose<br />being excreted as unchanged compound in the urine. The renal clearance is composed of<br />passive filtration and active secretion into the renal tubule.<br />Special populations<br />Elderly<br />A somewhat higher systemic exposure to valsartan was observed in some elderly subjects than<br />in young subjects; however, this has not been shown to have any clinical significance.<br />Limited data suggest that the systemic clearance of hydrochlorothiazide is reduced in both<br />healthy and hypertensive elderly subjects compared to young healthy volunteers.<br />Renal impairment<br />At the recommended dose of Arbaval Plus no dose adjustment is required for patients with a<br />Glomerular Filtration Rate (GFR) of 30&ndash;70 ml/min.<br />In patients with severe renal impairment (GFR &lt;30 ml/min) and patients undergoing dialysis no<br />data are available for Arbaval Plus. Valsartan is highly bound to plasma protein and is not to be<br />removed by dialysis, whereas clearance of hydrochlorothiazide will be achieved by dialysis.<br />In the presence of renal impairment, mean peak plasma levels and AUC values of<br />hydrochlorothiazide are increased and the urinary excretion rate is reduced. In patients with<br />mild to moderate renal impairment, a 3-fold increase in hydrochlorothiazide AUC has been<br />observed. In patients with severe renal impairment an 8-fold increase in AUC has been<br />observed. Hydrochlorothiazide is contraindicated in patients with severe renal impairment (see<br />section 4.3).<br />Hepatic impairment<br />In a pharmacokinetics trial in patients with mild (n=6) to moderate (n=5) hepatic dysfunction,<br />exposure to valsartan was increased approximately 2-fold compared with healthy volunteers<br />(see sections 4.2 and 4.4).<br />There is no data available on the use of valsartan in patients with severe hepatic dysfunction<br />(see section 4.3). Hepatic disease does not significantly affect the pharmacokinetics of<br />hydrochlorothiazide.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The potential toxicity of the valsartan - hydrochlorothiazide combination after oral<br />administration was investigated in rats and marmosets in studies lasting up to six months. No<br />findings emerged that would exclude the use of therapeutic doses in man.<br />The changes produced by the combination in the chronic toxicity studies are most likely to have<br />been caused by the valsartan component. The toxicological target organ was the kidney, the<br />reaction being more marked in the marmoset than the rat. The combination led to kidney<br />damage (nephropathy with tubular basophilia, rises in plasma urea, plasma creatinine and<br />serum potassium, increases in urine volume and urinary electrolytes from 30 mg/kg/day<br />valsartan + 9 mg/kg/day hydrochlorothiazide in rats and 10 + 3 mg/kg/d in marmosets),<br />probably by way of altered renal haemodynamics. These doses in rat, respectively, represent<br />0.9 and 3.5-times the maximum recommended human dose (MRHD) of valsartan and<br />hydrochlorothiazide on a mg/m2 basis. These doses in marmoset, respectively, represent 0.3<br />and 1.2-times the maximum recommended human dose (MRHD) of valsartan and<br />hydrochlorothiazide on a mg/m2 basis. (Calculations assume an oral dose of 320 mg/day<br />valsartan in combination with 25 mg/day hydrochlorothiazide and a 60-kg patient.)<br />High doses of the valsartan - hydrochlorothiazide combination caused falls in red blood cell<br />indices (red cell count, haemoglobin, haematocrit, from 100 + 31 mg/kg/d in rats and 30 + 9<br />mg/kg/d in marmosets). These doses in rat, respectively, represent 3.0 and 12 times the<br />maximum recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a<br />mg/m2 basis. These doses in marmoset, respectively, represent 0.9 and 3.5 times the maximum<br />recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a mg/m2 basis.<br />(Calculations assume an oral dose of 320 mg/day valsartan in combination with 25 mg/day<br />hydrochlorothiazide and a 60-kg patient).<br />In marmosets, damage was observed in the gastric mucosa (from 30 + 9 mg/kg/d). The<br />combination also led in the kidney to hyperplasia of the afferent aterioles (at 600 + 188<br />mg/kg/d in rats and from 30 + 9 mg/kg/d in marmosets). These doses in marmoset,<br />respectively, represent 0.9 and 3.5 times the maximum recommended human dose (MRHD) of<br />valsartan and hydrochlorothiazide on a mg/m2 basis. These doses in rat, respectively, represent<br />18 and 73 times the maximum recommended human dose (MRHD) of valsartan and<br />hydrochlorothiazide on a mg/m2 basis. (Calculations assume an oral dose of 320 mg/day<br />valsartan in combination with 25 mg/day hydrochlorothiazide and a 60-kg patient).<br />The above mentioned effects appear to be due to the pharmacological effects of high valsartan<br />doses (blockade of angiotensin II-induced inhibition of renin release, with stimulation of the<br />renin-producing cells) and also occur with ACE inhibitors. These findings appear to have no<br />relevance to the use of therapeutic doses of valsartan in humans.<br />The valsartan - hydrochlorothiazide combination was not tested for mutagenicity, chromosomal<br />breakage or carcinogenicity, since there is no evidence of interaction between the two<br />substances. However, these tests were performed separately with valsartan and<br />hydrochlorothiazide, and produced no evidence of mutagenicity, chromosomal breakage or<br />carcinogenicity.<br />In rats, maternally toxic doses of valsartan (600 mg/kg/day) during the last days of gestation<br />and lactation led to lower survival, lower weight gain and delayed development (pinna<br />detachment and ear-canal opening) in the offspring (see section 4.6). These doses in rats (600<br />mg/kg/day) are approximately 18 times the maximum recommended human dose on a mg/m2<br />basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient). Similar findings<br />were seen with valsartan/hydrochlorothiazide in rats and rabbitsIn embryo-fetal development<br />(Segment II) studies with valsartan/hydrochlorothiazide in rat and rabbit, there was no<br />evidence of teratogenicity; however, fetotoxicity associated with maternal toxicity was<br />observed.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Silicified Microcrystalline Cellulose<br />Crospovidone<br />Sodium Starch Glycolate<br />Magnesium Stearate<br />Opadry Yellow<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg; C. Store in the original package in order to protect from moisture.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminum/ Aluminum blisters.<br />Packs of 28 film-coated tablets<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SAJA Pharmaceuticals
Saudi Arabian Japanese pharmaceutical company limited
Jeddah – Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                08/ 2014
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>